NutriBand (NTRB) Share-based Compensation (2017 - 2026)
NutriBand (NTRB) posted Share-based Compensation of $552458.0 for Q2 2026, up 142.99% sequentially from -$1.3 million in Q1 2026, and up 772.07% YoY from $63350.0 in Q2 2025.
NutriBand (NTRB) Share-based Compensation (2017 - 2026) Analysis & Trends
NutriBand has reported Share-based Compensation for 10 years, with the latest figure at $552458.0 in Q2 2026.
- Quarterly Share-based Compensation rose 772.07% year-over-year to $552458.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.7 million (up 65.76% YoY) and the FY2026 annual result came in at $1.3 million, down 11.26% from the prior year.
- Share-based Compensation improved to $552458.0 in Q2 2026 per NTRB's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.4 million in Q4 2025 and troughed at -$1.3 million in Q1 2026.
- A 5-year average of $281548.7 and a median of $75030.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 772.07% in 2026, down 200.76% in 2026.
- Over 5 years, Share-based Compensation stood at -$71435.0 in 2022, then surged by 694.7% to $424826.0 in 2023, then plunged by 198.86% to -$419985.0 in 2024, then soared by 678.85% to $2.4 million in 2025, then plunged by 77.28% to $552458.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $552458.0, -$1.3 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | NutriBand | 54.82 Mn | 50.82 Mn | 196,801.00 | 552,458.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 552,458.00 |
| Apr 30, 2026 | 552,458.00 |
| Jan 31, 2026 | -1.29 Mn |
| Jan 31, 2026 | -1.29 Mn |
| Oct 31, 2025 | 2.43 Mn |
| Oct 31, 2025 | 2.43 Mn |
| Jul 31, 2025 | 41,050.00 |
| Jul 31, 2025 | 41,050.00 |
| Apr 30, 2025 | 63,350.00 |
| Apr 30, 2025 | 63,350.00 |
| Jan 31, 2025 | 1.28 Mn |
| Jan 31, 2025 | 1.28 Mn |
| Oct 31, 2024 | -419,985.00 |
| Oct 31, 2024 | -419,985.00 |
| Jul 31, 2024 | 130,380.00 |
| Jul 31, 2024 | 130,380.00 |
| Apr 30, 2024 | 422,955.00 |
| Apr 30, 2024 | 422,955.00 |
| Oct 31, 2023 | 424,826.00 |
| Oct 31, 2023 | 424,826.00 |